We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




World’s Fastest DNA Sequencing Technique to Revolutionize NICU Genomic Care

By LabMedica International staff writers
Posted on 28 Oct 2025

When critically ill newborns enter the NICU, every minute matters — yet traditional genetic testing can take several days to deliver results. More...

Many infants with rare genetic disorders deteriorate quickly while clinicians wait for diagnostic insights to guide treatment. Now, researchers have developed a groundbreaking workflow capable of performing rapid genomic sequencing and analysis in just hours, setting a world record for the fastest human whole genome sequencing to date.

The breakthrough comes from a collaboration between Boston Children’s Hospital (Boston, MA, USA), Broad Clinical Labs (Cambridge, MA, USA), and Roche Sequencing Solutions (Pleasanton, CA, USA). Together, the team demonstrated that ultra-fast genome sequencing and interpretation can move from concept to clinical reality, potentially reshaping genetic diagnostics for infants in critical care.

The process used Roche’s Sequencing by Expansion (SBX) prototype — an advanced platform that sequences and interprets DNA at unprecedented speed. Researchers at Broad Clinical Labs applied the technology to 15 human samples, including seven from Boston Children’s NICU and five historical cases from the hospital’s Manton Center for Orphan Disease Research. The fastest genome analysis was completed in under four hours, identifying genetic variants directly from the extracted DNA.

Current rapid genomic sequencing methods available in hospitals typically take several days from sample receipt to report generation. In contrast, the new approach compresses this timeframe to mere hours, offering the possibility for same-day diagnosis and treatment. The pilot study results, published in the New England Journal of Medicine, mark a transformative step for genetic medicine in neonatal intensive care, allowing physicians to move from broad, symptom-based approaches to precise, gene-informed treatment decisions.

With proof-of-concept success, the team envisions scaling this technology for broader hospital use, enabling rapid, on-demand sequencing across critical care units. Such an advancement could redefine how hospitals approach the diagnosis and treatment of rare diseases, giving doctors and families vital answers when they are needed most.

“Our pilot simulates a workflow through which we could feasibly send out a genome sequencing sample from a baby in the morning and have the diagnosis/report that same afternoon,” said Monica Wojcik, MD, MPH, the study’s first author. “In the NICU, a few hours could mean the difference between unnecessary procedures and targeted, life-saving treatment. The results of this study bring geneticists and clinicians one step closer to integrating point-of-care genome sequencing into the standard of care for critical care settings.”

Related Links:
Boston Children’s Hospital
Broad Clinical Labs
Roche Sequencing Solutions 


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.